Hepatitis Clinical Trials in Richmond, Virginia
17 recruitingRichmond, Virginia
Showing 1–17 of 17 trials
Recruiting
Phase 2
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
Alcohol Associated Hepatitis
Samer Gawrieh216 enrolled6 locationsNCT07060638
Recruiting
Phase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled447 locationsNCT06632457
Recruiting
Phase 3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
MASH - Metabolic Dysfunction-Associated SteatohepatitisNASH - Nonalcoholic Steatohepatitis
Akero Therapeutics, Inc2,150 enrolled322 locationsNCT06528314
Recruiting
Phase 2
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis
Eccogene160 enrolled58 locationsNCT07288138
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
89bio, Inc.762 enrolled303 locationsNCT06419374
Recruiting
Phase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
89bio, Inc.1,350 enrolled349 locationsNCT06318169
Recruiting
Phase 2
Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
CirrhosisCirrhosis, LiverCirrhosis Due to Hepatitis B+5 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)256 enrolled13 locationsNCT05832229
Recruiting
Phase 1
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection
Hepatitis B Virus Infection
GigaGen, Inc.48 enrolled17 locationsNCT07024641
Recruiting
Not Applicable
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
NASH - Nonalcoholic Steatohepatitis
Perspectum225 enrolled7 locationsNCT04054310
Recruiting
Phase 2
A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Metabolic dysfunction-associated steatohepatitis (MASH)
Regeneron Pharmaceuticals120 enrolled71 locationsNCT05519475
Recruiting
Phase 3
Study to Evaluate the Safety and Efficacy of Larsucosterol in Participants With Alcohol-associated Hepatitis (AH)
Hepatitis
Bausch Health Americas, Inc.350 enrolled48 locationsNCT07428538
Recruiting
Predicting Outcomes in Nonalcoholic Steatohepatitis With Advanced Fibrosis
Nonalcoholic Steatohepatitis
Virginia Commonwealth University240 enrolled2 locationsNCT05720663
Recruiting
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic SteatohepatitisNonalcoholic Fatty Liver
Target PharmaSolutions, Inc.15,000 enrolled74 locationsNCT02815891
Recruiting
Phase 2
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis
Boston Pharmaceuticals42 enrolled35 locationsNCT06920043
Recruiting
Phase 4
National Liver Cancer Screening Trial
Liver CancerCarcinoma, HepatocellularLiver Cirrhosis+1 more
University of Texas Southwestern Medical Center5,500 enrolled18 locationsNCT06084234
Recruiting
Phase 2
FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study
Alcohol Associated Hepatitis
Intercept Pharmaceuticals80 enrolled31 locationsNCT05639543